公司概述
Cryo-Cell International, Inc. operates within the healthcare sector, specifically functioning in the medical care facilities industry by providing cord blood and cord tissue cryopreservation services in the United States. The company's core business involves offering cellular processing and cryogenic storage solutions primarily designed for family use, focusing on the collection and preservation of umbilical cord blood and tissue stem cells. In terms of scale, the company maintains a market capitalization of $29.80M, generated annual revenue of $31.57M, and employs a workforce of 72 individuals. These valuation and revenue figures indicate that the company operates as a small-cap entity with a revenue base that suggests a specialized niche position rather than broad market dominance.
财务健康
The company reported revenue of $31.57M over the trailing twelve months, with a net income of -$2,429,385 and an EBITDA of $1.47M. The significant negative gap between the positive revenue figure and the substantial net loss reveals a cost structure where operating expenses, including likely high fixed costs associated with cryogenic storage and regulatory compliance, are outpacing gross profitability. Despite the accounting loss, the entity generated positive free cash flow of $580,321, which indicates a degree of financial flexibility by allowing the company to cover operational outflows and potentially fund working capital without immediate external financing. The gross margin stands at 62.8%, reflecting a relatively efficient cost of goods sold typical for service-based biotechnology firms, whereas the operating margin is negative at -50.6% and the profit margin is -7.7%, signaling that general and administrative expenses are eroding a significant portion of the gross profit before reaching the bottom line. On the balance sheet, total cash of $3.30M is substantially lower than the total debt of $11.56M, and the debt-to-equity ratio is listed as N/A, suggesting a highly leveraged capital structure where equity value may be negative or negligible relative to obligations. The current ratio of 0.59 indicates that current assets are insufficient to cover current liabilities, pointing to potential short-term liquidity constraints. Return on equity is N/A due to the equity structure, while return on assets is 0.5%, which reveals limited management effectiveness in generating returns on the asset base relative to the size of the operations.
估值评估
The trailing P/E ratio is N/A due to the negative earnings, while the forward P/E is 46.25, implying that the market is pricing in significant expected earnings recovery or turnaround to justify the current multiple. The price-to-book ratio is negative at -1.60, which indicates that the market capitalization is valued below the company's book value, a metric often seen in distressed or loss-making firms rather than those commanding a premium over tangible assets. Alternative valuation metrics such as the price-to-sales ratio of 0.94 and the EV/EBITDA of 25.94 suggest that investors are valuing the company primarily on its revenue generation and EBITDA potential rather than current profitability. The stock traded within a 52-week range with a high of $6.35 and a low of $2.72, meaning the current market price sits between these extremes, reflecting the volatility typical of small-cap biotech firms. The beta value of 0.63 suggests that the stock's price volatility is lower than that of the broader market, indicating less sensitivity to general market movements compared to large-cap equities.
Growth & Income
Revenue growth year-over-year declined by 2.3%, while earnings growth is N/A, indicating that the company is currently contracting in revenue and unable to generate positive earnings to support growth metrics. The company does not appear to be a sustainable dividend payer given the payout ratio of 3962.9% and the negative net income, as paying dividends out of losses is generally not feasible for long-term sustainability. Instead of distributing cash flow, the company likely reinvests its available free cash flow of $580,321 into operational growth, research, or debt reduction rather than paying dividends to shareholders. The overall growth and income profile is characterized by revenue contraction, a lack of profitability, and an absence of dividend income, presenting a high-risk scenario reliant on future operational improvements.